Thérapie ciblée MORTALITY Gene expression Contraindication Stricture RISK Rituximab plus chlorambucil MICROBIOTA Dysbiosis 18 FDG-PET/CT Small molecules Safety Biologics Primary sclerosing cholangitis MALT Endoscopic treatment Upper gastrointestinal tract Résistance Disease Progression Immune cells Dysbiose Anti-TNF agents Biomarker Colorectal cancer Colibactin and lipids Therapeutics Disability Immunosuppressant Ustekinumab Colon Neoadjuvant chemotherapy COLON-CANCER Inflammatory Bowel Diseases HIV Over 80s Survival IL23 Colectomy Intestinal crypts Screening Anti-TNF Eligibility Microbiota Inflammatory bowel disease Heart disease risk factors Inhibitor Colorectal cancer Tuberculosis Bactéries Methylation Surgery IL12 Colonic epithelial primary cells DNA METHYLATION Gènes Consensus Original Article Clinical PCR Inflammatory bowel diseases Eradication Cell adhesion Epigenetics Cost effectiveness Colon cancer MARKER IBD Clinical guidelines Parvimonas micra Bacteria Crohn's disease Gene methylation Cancer Disease progression Vedolizumab Maintenance therapy Ulcerative colitis Effectiveness Genes Méthylation Epigénétiques Venous thromboembolism T1118 translocation Patient-reported outcome DNA methylation Algorithm Clinical trial Monitoring Patients experience Drug Rituximab Fecal microbiota Tailored therapy Helicobacter pylori Microbiote Kidney diseases Crohn’s disease Acceptability Inclusion Resistance CARCINOGENESIS Alkylating agents